CHICAGO, June 15, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided an update on its United States market entry through the "18 Series," a science-driven nutraceutical platform built on proprietary ingredients, published clinical research, and exact clinical dosing, and disclosed projected annualized revenue and implied gross profit for four of its launched products.

Cosmos Health_18_Series_US_Summary

Since launching the 18 Series in the U.S., Cosmos Health has introduced five products: Noor18™, Liv18™, Cur18™, Fort18™, and Oliv18™ — four of which currently have disclosed projections. The Company has observed encouraging early demand and continues to build commercial traction in the U.S. market.

Across the four products with disclosed projections to date, Cosmos Health is targeting over $22.7 million in annualized U.S. revenue and approximately $17.0 million in implied gross profit at ~75% gross margins.

18 Series — Announced U.S. Revenue and Gross Profit Projections

Product	Category	Projected Annualized U.S. Revenue	Gross Profit¹
Noor18™	Healthy aging / beauty	Over $12.0M	~$9.00M
Liv18™	Liver & metabolic support	Over $5.0M	~$3.75M
Fort18™	Men's wellness	Over $3.2M	~$2.40M
Cur18™	Inflammation & mobility	Over $2.5M	~$1.875M
Total		Over $22.7M	~$17.0M

¹ Gross profit is calculated by applying the Company's approximately 75% gross-margin guidance to its disclosed revenue projections. Total excludes Oliv18™, which is launched but has no disclosed revenue projection.

The 18 Series platform remains at an early stage. Cosmos Health is targeting a portfolio of 18 science-based products spanning key health categories, and expects to provide further updates as additional products are launched and commercial data develops.

The Company expects its U.S. 18 Series to become a significant pillar of long-term revenue and a meaningful contributor to profitability.

Greg Siokas, CEO of Cosmos Health, stated: "Our U.S. entry is active, generating revenue, and showing encouraging early momentum. The platform is still at an early stage — we are targeting a portfolio of 18 science-based products — but we already expect the 18 Series to become a key engine of our growth. Today we sell direct-to-consumer, and over time we intend to expand into additional retail channels as we scale. We look forward to providing further updates as the platform develops."

"Cosmos Health is at a turning point, with a sharpened focus on profitability as we move the business to a different level. In addition, we are pleased to be working on new projects in the United States that extend beyond the nutraceutical space, which we expect will further improve profitability and cash generation."

About the 18 Series:

The 18 Series is Cosmos Health's science-driven U.S. nutraceutical platform, built on proprietary ingredients, published clinical research, and exact clinical dosing. The Company is targeting a portfolio of 18 products spanning key health and wellness categories, introduced through a direct-to-consumer model with planned expansion into additional channels over time. All products are manufactured in the U.S. at GMP-certified, FDA-registered facilities.

No statement made herein has been evaluated by the U.S. Food and Drug Administration. Any product described above is not intended to diagnose, treat, cure, or prevent any disease.

About Cosmos Health Inc.

Cosmos Health Inc. (NASDAQ:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; the Company's ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC's website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.

Investor Relations Contact:

BDG Communications

cosm@bdgcommunications.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c5de5aec-c977-468c-ba84-6d090ffa5825

Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit